The British government announced on Friday a one-off MenB vaccination programme for thousands of students across England, responding to the country’s largest and fastest-growing outbreak of meningococcal B disease on record. Two people died in March during an outbreak in Kent, southeast England, that health authorities described as the largest and fastest-growing ever seen in Britain. The programme, confirmed by the Department of Health and Social Care, will begin in July 2026.
Eligible students will be offered a two-dose vaccination before they start university, where close and prolonged contact in halls and at social events increases the risk of contracting MenB disease. Both doses are required for protection to take effect.
The outbreak is thought to have originated at a nightclub in Canterbury. A 21-year-old university student and Juliette, a sixth-former at Queen Elizabeth’s Grammar School in Faversham, died as the number of confirmed and suspected cases reached 20.
The scale of this year’s spread went beyond Kent. While the response to the Kent incident has concluded, there have been more clusters than normal this year, some of which have been bigger than expected. Separate clusters emerged in Weymouth and Reading, according to the Meningitis Research Foundation.
UKHSA data shows there were 313 confirmed cases of Meningococcal Group B in England during 2024/25, accounting for approximately 83% of all invasive meningococcal disease cases, disproportionately affecting young adults and teenagers.
Secretary of State for Health and Social Care James Murray said the situation suggested the disease may be shifting in how it behaves. “The Kent outbreak and recent clusters indicate a possible change to the way MenB affects people,” he said. “While we assess the latest evidence, we are acting now to help protect young people at highest immediate risk as they enter university and residential colleges this autumn.”
Murray added that the one-off programme will cover people who complete Year 13 in summer 2026, born between 1 September 2007 and 31 August 2008, as well as those under 25 starting university or moving into residential further education for the first time in autumn 2026. Post-graduates and students entering their second or later year are not covered.
Deputy Chief Medical Officer Dr Thomas Waite said: “There has been an increase in clusters of disease this year and so this one-off programme is designed to provide direct protection to those at highest immediate risk which is typically when students travel from across the country to attend university and further education for the first time.”
Waite confirmed that two doses, taken at least four weeks apart, are needed for maximum protection.
The NHS has begun operational rollout planning, with vaccinations expected to be available from the end of July 2026, ahead of the new academic year. Appointments will be available at community pharmacies. Those eligible will be contacted directly through the NHS App, by text, email, or letter depending on the records held by the health service. Bookings open in mid-July.
International students under 25 entering their first year of university are advised to receive their first dose in their home country where possible.
The MenB vaccine is not new to the NHS. It already features in the NHS childhood vaccination programme for infants, and evidence shows vaccination has led to around a 75% reduction in MenB disease among eligible vaccinated groups. Its safety record is established — the extension to older age groups is what is new.
Vinny Smith, Chief Executive of the Meningitis Research Foundation, welcomed the speed of the decision. “Having supported thousands of people during the Kent outbreak, and as clusters of cases emerged in Weymouth and Reading this year, we know how important fast action is,” he said. Smith added that the programme represents “a major step towards closing the MenB protection gap for teens and young adults in the UK.”
Dr Tom Nutt, Chief Executive of Meningitis Now, said the announcement was the result of years of campaigning. His organisation has run the “No Plan B for MenB” campaign, pushing for broader access to the vaccine. Nutt called it “a major step forward” but said further work remains. “There is still more work to do to ensure everyone at risk is protected, including those already at university and younger teenagers,” he said.
Why this matters
Meningococcal disease is life-threatening and can result in life-changing disabilities such as amputations, hearing loss, and brain damage. It is fatal in around 10% of cases. The disease spreads through close contact — kissing, sharing drinks, or prolonged time in shared living spaces — making university environments particularly high-risk.
UKHSA estimates that the relative risk of invasive MenB disease in first-year university students is substantially greater than in their peers, and cases of invasive meningococcal disease tend to peak in October and November each year. The July–August vaccine window is designed to pre-empt that seasonal spike.
For the broader public health system, the programme marks a notable policy shift. The Joint Committee on Vaccination and Immunisation (JCVI) has so far provided the government with an assessment of priorities for a one-off targeted programme. Further advice from the JCVI on considerations for a longer programme will follow. That assessment could expand eligibility significantly.
Background
MenB is caused by the bacterium Neisseria meningitidis group B and is among the most dangerous strains of bacterial meningitis. The UK had 378 confirmed cases of the infection from July 2024 through June 2025; the US reported 503 confirmed and probable cases in 2024. Transmission requires close and prolonged contact, which is why outbreaks are uncommon but occur more frequently under special risk conditions such as crowded settings. The Kent outbreak, which began in March 2026, prompted an immediate emergency vaccination drive at the University of Kent campus in Canterbury, with approximately 5,000 students targeted in the initial response. The government’s new national programme goes substantially further.
What happens next
Vaccine appointment bookings open in mid-July 2026, with the first doses available from the end of July. The second dose follows in August, at least four weeks after the first. The Department of Health and Social Care, NHS England, and UKHSA will run a coordinated public information campaign to drive uptake. The JCVI is also updating its assessment of appropriate eligibility for routine MenB vaccination, with advice to be provided to ministers as soon as possible. That review could lead to a permanent expansion of the NHS vaccination schedule for older age groups.
